Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone
We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function. Recently, ARBs are replacing the ACE inhibitors. The combined therapy...
Gespeichert in:
| Veröffentlicht in: | Kobe journal of the medical sciences 2005, Vol.51 (1-2), p.1 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1-2 |
| container_start_page | 1 |
| container_title | Kobe journal of the medical sciences |
| container_volume | 51 |
| creator | Fujii, Hideki Nakahama, Hajime Yoshihara, Fumiki Nakamura, Satoko Inenaga, Takashi Kawano, Yuhei |
| description | We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function. Recently, ARBs are replacing the ACE inhibitors. The combined therapy with ARB and spironolactone will eventually become the standard regimen. The strict attention and close monitoring of serum potassium should be mandatory in combination therapy to prevent hyperkalemia. Assessment of trans-tubular potassium gradient (TTKG) and fractional excretion of potassium (FEK) before starting the therapy would help in identifying the patients at higher risk of developing hyperkalemia. Co-administration of thiazide or loop diuretics is recommended to reduce the risk of hyperkalemia. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_16199929</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16199929</sourcerecordid><originalsourceid>FETCH-LOGICAL-j236t-2225953e31fa3f771bfe755638644e93f7acee1ac61c546445789506186554983</originalsourceid><addsrcrecordid>eNo1kE1qwzAUhLVoadK0Vyi6gMGSLNlaltA_CHTTrsOz_BwrsSUhKRRDD1-HtqthPmZmMVdkXZZcFFwysSK3KR0Xq6qa3ZAVU0xrzfWafO9sj0UeIkJGZ92BDnPAeIIRJwu0O8cLA2r81FqHHc0DRggz_bJ5uBgK7mD90k3W0YgGQ_aRtqM3J4zUgOswQczglmBHU7DROz-Cyd7hHbnuYUx4_6cb8vn89LF9LXbvL2_bx11x5ELlgnMutRQoWA-ir2vW9lhLqUSjqgr1gsAgMjCKGVktTNaNlqVijZKy0o3YkIff3XBuJ-z2IdoJ4rz_v0H8APWDWqA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone</title><source>MEDLINE</source><source>Freely Accessible Japanese Titles</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Fujii, Hideki ; Nakahama, Hajime ; Yoshihara, Fumiki ; Nakamura, Satoko ; Inenaga, Takashi ; Kawano, Yuhei</creator><creatorcontrib>Fujii, Hideki ; Nakahama, Hajime ; Yoshihara, Fumiki ; Nakamura, Satoko ; Inenaga, Takashi ; Kawano, Yuhei</creatorcontrib><description>We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function. Recently, ARBs are replacing the ACE inhibitors. The combined therapy with ARB and spironolactone will eventually become the standard regimen. The strict attention and close monitoring of serum potassium should be mandatory in combination therapy to prevent hyperkalemia. Assessment of trans-tubular potassium gradient (TTKG) and fractional excretion of potassium (FEK) before starting the therapy would help in identifying the patients at higher risk of developing hyperkalemia. Co-administration of thiazide or loop diuretics is recommended to reduce the risk of hyperkalemia.</description><identifier>ISSN: 0023-2513</identifier><identifier>PMID: 16199929</identifier><language>eng</language><publisher>Japan</publisher><subject>Angiotensin II Type 1 Receptor Blockers - administration & dosage ; Angiotensin II Type 1 Receptor Blockers - adverse effects ; Benzimidazoles - administration & dosage ; Benzimidazoles - adverse effects ; Diuretics - administration & dosage ; Diuretics - adverse effects ; Drug Therapy, Combination ; Female ; Humans ; Hyperkalemia - chemically induced ; Hypertension - complications ; Hypertension - drug therapy ; Middle Aged ; Nephrosclerosis - complications ; Nephrosclerosis - drug therapy ; Spironolactone - administration & dosage ; Spironolactone - adverse effects ; Tetrazoles - administration & dosage ; Tetrazoles - adverse effects</subject><ispartof>Kobe journal of the medical sciences, 2005, Vol.51 (1-2), p.1</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16199929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fujii, Hideki</creatorcontrib><creatorcontrib>Nakahama, Hajime</creatorcontrib><creatorcontrib>Yoshihara, Fumiki</creatorcontrib><creatorcontrib>Nakamura, Satoko</creatorcontrib><creatorcontrib>Inenaga, Takashi</creatorcontrib><creatorcontrib>Kawano, Yuhei</creatorcontrib><title>Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone</title><title>Kobe journal of the medical sciences</title><addtitle>Kobe J Med Sci</addtitle><description>We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function. Recently, ARBs are replacing the ACE inhibitors. The combined therapy with ARB and spironolactone will eventually become the standard regimen. The strict attention and close monitoring of serum potassium should be mandatory in combination therapy to prevent hyperkalemia. Assessment of trans-tubular potassium gradient (TTKG) and fractional excretion of potassium (FEK) before starting the therapy would help in identifying the patients at higher risk of developing hyperkalemia. Co-administration of thiazide or loop diuretics is recommended to reduce the risk of hyperkalemia.</description><subject>Angiotensin II Type 1 Receptor Blockers - administration & dosage</subject><subject>Angiotensin II Type 1 Receptor Blockers - adverse effects</subject><subject>Benzimidazoles - administration & dosage</subject><subject>Benzimidazoles - adverse effects</subject><subject>Diuretics - administration & dosage</subject><subject>Diuretics - adverse effects</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperkalemia - chemically induced</subject><subject>Hypertension - complications</subject><subject>Hypertension - drug therapy</subject><subject>Middle Aged</subject><subject>Nephrosclerosis - complications</subject><subject>Nephrosclerosis - drug therapy</subject><subject>Spironolactone - administration & dosage</subject><subject>Spironolactone - adverse effects</subject><subject>Tetrazoles - administration & dosage</subject><subject>Tetrazoles - adverse effects</subject><issn>0023-2513</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1qwzAUhLVoadK0Vyi6gMGSLNlaltA_CHTTrsOz_BwrsSUhKRRDD1-HtqthPmZmMVdkXZZcFFwysSK3KR0Xq6qa3ZAVU0xrzfWafO9sj0UeIkJGZ92BDnPAeIIRJwu0O8cLA2r81FqHHc0DRggz_bJ5uBgK7mD90k3W0YgGQ_aRtqM3J4zUgOswQczglmBHU7DROz-Cyd7hHbnuYUx4_6cb8vn89LF9LXbvL2_bx11x5ELlgnMutRQoWA-ir2vW9lhLqUSjqgr1gsAgMjCKGVktTNaNlqVijZKy0o3YkIff3XBuJ-z2IdoJ4rz_v0H8APWDWqA</recordid><startdate>2005</startdate><enddate>2005</enddate><creator>Fujii, Hideki</creator><creator>Nakahama, Hajime</creator><creator>Yoshihara, Fumiki</creator><creator>Nakamura, Satoko</creator><creator>Inenaga, Takashi</creator><creator>Kawano, Yuhei</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>2005</creationdate><title>Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone</title><author>Fujii, Hideki ; Nakahama, Hajime ; Yoshihara, Fumiki ; Nakamura, Satoko ; Inenaga, Takashi ; Kawano, Yuhei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j236t-2225953e31fa3f771bfe755638644e93f7acee1ac61c546445789506186554983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Angiotensin II Type 1 Receptor Blockers - administration & dosage</topic><topic>Angiotensin II Type 1 Receptor Blockers - adverse effects</topic><topic>Benzimidazoles - administration & dosage</topic><topic>Benzimidazoles - adverse effects</topic><topic>Diuretics - administration & dosage</topic><topic>Diuretics - adverse effects</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperkalemia - chemically induced</topic><topic>Hypertension - complications</topic><topic>Hypertension - drug therapy</topic><topic>Middle Aged</topic><topic>Nephrosclerosis - complications</topic><topic>Nephrosclerosis - drug therapy</topic><topic>Spironolactone - administration & dosage</topic><topic>Spironolactone - adverse effects</topic><topic>Tetrazoles - administration & dosage</topic><topic>Tetrazoles - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fujii, Hideki</creatorcontrib><creatorcontrib>Nakahama, Hajime</creatorcontrib><creatorcontrib>Yoshihara, Fumiki</creatorcontrib><creatorcontrib>Nakamura, Satoko</creatorcontrib><creatorcontrib>Inenaga, Takashi</creatorcontrib><creatorcontrib>Kawano, Yuhei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Kobe journal of the medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fujii, Hideki</au><au>Nakahama, Hajime</au><au>Yoshihara, Fumiki</au><au>Nakamura, Satoko</au><au>Inenaga, Takashi</au><au>Kawano, Yuhei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone</atitle><jtitle>Kobe journal of the medical sciences</jtitle><addtitle>Kobe J Med Sci</addtitle><date>2005</date><risdate>2005</risdate><volume>51</volume><issue>1-2</issue><spage>1</spage><pages>1-</pages><issn>0023-2513</issn><abstract>We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function. Recently, ARBs are replacing the ACE inhibitors. The combined therapy with ARB and spironolactone will eventually become the standard regimen. The strict attention and close monitoring of serum potassium should be mandatory in combination therapy to prevent hyperkalemia. Assessment of trans-tubular potassium gradient (TTKG) and fractional excretion of potassium (FEK) before starting the therapy would help in identifying the patients at higher risk of developing hyperkalemia. Co-administration of thiazide or loop diuretics is recommended to reduce the risk of hyperkalemia.</abstract><cop>Japan</cop><pmid>16199929</pmid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0023-2513 |
| ispartof | Kobe journal of the medical sciences, 2005, Vol.51 (1-2), p.1 |
| issn | 0023-2513 |
| language | eng |
| recordid | cdi_pubmed_primary_16199929 |
| source | MEDLINE; Freely Accessible Japanese Titles; EZB-FREE-00999 freely available EZB journals |
| subjects | Angiotensin II Type 1 Receptor Blockers - administration & dosage Angiotensin II Type 1 Receptor Blockers - adverse effects Benzimidazoles - administration & dosage Benzimidazoles - adverse effects Diuretics - administration & dosage Diuretics - adverse effects Drug Therapy, Combination Female Humans Hyperkalemia - chemically induced Hypertension - complications Hypertension - drug therapy Middle Aged Nephrosclerosis - complications Nephrosclerosis - drug therapy Spironolactone - administration & dosage Spironolactone - adverse effects Tetrazoles - administration & dosage Tetrazoles - adverse effects |
| title | Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T07%3A16%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Life-threatening%20hyperkalemia%20during%20a%20combined%20therapy%20with%20the%20angiotensin%20receptor%20blocker%20candesartan%20and%20spironolactone&rft.jtitle=Kobe%20journal%20of%20the%20medical%20sciences&rft.au=Fujii,%20Hideki&rft.date=2005&rft.volume=51&rft.issue=1-2&rft.spage=1&rft.pages=1-&rft.issn=0023-2513&rft_id=info:doi/&rft_dat=%3Cpubmed%3E16199929%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16199929&rfr_iscdi=true |